Imugene Pink Sheet Quote Today

Imugene Limited is currently unavailable and cannot be used in your analysis. The information on this page reflects the last day Imugene was actively traded. Please check the pink sheet traded under the symbol IUGNF.
Valuation
Check how we calculate scores

Imugene Pink Sheet Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Imugene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Imugene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Imugene Limited is now traded under the symbol IUGNF. Please update your portfolios or report it if you believe this is an error. Report It!
CEO, Managing DirectorLeslie Chong
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Imugene's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedFairly Valued
Imugene Limited [IUGNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Small-Cap' category with a current market capitalization of 699.33 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Imugene's market, we take the total number of its shares issued and multiply it by Imugene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Imugene Limited classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 6.42 B outstanding shares. Imugene Limited has accumulated about 99.89 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Imugene Probability Of Bankruptcy

Imugene Stock Price Odds Analysis

What are Imugene's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Imugene jumping above the current price in 90 days from now is more than 94.0%. The Imugene Limited probability density function shows the probability of Imugene pink sheet to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Imugene Limited has a beta of -0.9175. This usually indicates Additionally, the company has an alpha of 0.1315, implying that it can generate a 0.13 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.1HorizonTargetOdds Above 0.1
6.01%90 days
 0.10 
93.95%
Based on a normal probability distribution, the odds of Imugene to move above the current price in 90 days from now is more than 94.0 (This Imugene Limited probability density function shows the probability of Imugene Pink Sheet to fall within a particular range of prices over 90 days) .

Imugene Limited Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Imugene market risk premium is the additional return an investor will receive from holding Imugene long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Imugene. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Imugene's alpha and beta are two of the key measurements used to evaluate Imugene's performance over the market, the standard measures of volatility play an important role as well.

Imugene Stock Against Markets

Picking the right benchmark for Imugene pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Imugene pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Imugene is critical whether you are bullish or bearish towards Imugene Limited at a given time.

Delisting Warning - IUGNF

Imugene Limited was delisted

  The entity Imugene Limited with a symbol IUGNF was delisted from PINK Exchange. Please use Imugene Limited with a symbol IUGNF from now on.

Imugene Corporate Management

Elected by the shareholders, the Imugene's board of directors comprises two types of representatives: Imugene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imugene. The board's role is to monitor Imugene's management team and ensure that shareholders' interests are well served. Imugene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imugene's outside directors are responsible for providing unbiased perspectives on the board's policies.
BA ASiA - Ex ChairmanProfile
Anthony Good - VP ResearchProfile
Nathan CA - Joint SecProfile
Ursula Wiedermann - Chief Scientific OfficerProfile
PharmD MBA - Chief OfficerProfile

Invested in Imugene Limited?

The danger of trading Imugene Limited is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Imugene is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Imugene. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Imugene Limited is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please see Risk vs Return Analysis. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Tools for Imugene Pink Sheet

When running Imugene Limited price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities